Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients
Status:
Active, not recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of 3-drug all-oral combination, ixazomib
plus lenalidomide plus dexamethasone (IRd) as induction treatment for autologous stem cell
transplantation eligible patients followed by IRd consolidation and risk based maintenance
treatment with IR or R alone.